Postmenopausal estrogen therapy and cardiovascular disease

Barbara J. Fleming, Jerilynn C. Prior, David Atkins, David B. Maclean, Andrew Bostom, Meir J. Stampfer, Graham A. Colditz, Walter C. Willett, Joann E. Manson, Bernard Rosner, Frank E. Speizer, Charles H. Hennekens

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: As the benefits of antiestrogen therapy in preventing or delaying the recurrence of breast cancer continue to be documented, as Stampfer et al. (Sept. 12 issue)* have done, more and more women will receive tamoxifen or other antiestrogen therapy for many years. There are also many who may not be receiving antiestrogen therapy, but who should certainly not be receiving estrogen replacement after estrogen-receptor—positive breast carcinoma. If estrogen replacement is protective against the development of osteoporosis and cardiovascular disease in postmenopausal women, what advice should we be giving to the increasingly large population of women who have.

Original languageEnglish
Pages (from-to)705-708
Number of pages4
JournalNew England Journal of Medicine
Issue number10
StatePublished - Mar 5 1992


Dive into the research topics of 'Postmenopausal estrogen therapy and cardiovascular disease'. Together they form a unique fingerprint.

Cite this